Is once-weekly epoetin beta 'highly effective' in treating anaemia in patients with lymphoproliferative malignancy? [7]

British Journal of Haematology

Volumn 125, Issue 1, 2004, Pages 98-99

  Bokemeyer, Carsten ^a   Littlewood, Tim ^b   Aapro, Matti ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Anaemia; Epoetin beta; Erythropoietin; Lymphoproliferative malignancy; Once weekly administration

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN DETERMINATION; HUMAN; LETTER; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANEMIA; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; LYMPHOPROLIFERATIVE DISORDERS;

EID: 1842610152     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.04885.x     Document Type: Letter

References (1)

1. Cazzola, M., Beguin, Y., Kloczko, J., Spicka, I. & Coiffier, B. (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. British Journal of Haematology, 122, 386-393.